Novo Nordisk is negotiating pricing agreements with healthcare systems in multiple countries for the "miracle weight loss medicine"
永远爱你冰使
发表于 2023-11-27 18:13:56
1378
0
0
According to media reports, Danish pharmaceutical giant Novo Nordisk is negotiating an innovative pricing agreement for its weight loss drug Wegovy with healthcare systems in some countries. The company hopes to help medical service institutions allocate costs over the years through agreements, thereby expanding Wegovy's market share.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- The US Senate questions whether the pricing of the "weight loss miracle drug" is too high. Nuo and Nuo De respond that lowering the price is useless
- Tianjing Biotechnology and Sanofi have reached an authorization agreement with a potential total price of up to 200 million euros
- OPEC+reportedly strengthens supervision and vows to reshape the authority of the production reduction agreement
- Novo Nordisk to invest 864 million Brazilian reals to renovate insulin factory in Brazil
- Novo Nordisk to invest 864 million Brazilian reals to renovate insulin factory in Brazil
- Novo Nordisk reaches settlement with Mylan Pharmaceuticals over patent dispute over weight loss drug Ozempic and Wegovy
- Nokia and Chunghwa Telecom reach extension agreement on 5G Advanced
- Novo Nordisk has participated in the CIIE for seven consecutive years, working together with various sectors to promote the concept of "healthy metabolism"
- Novo Nordisk warns of the risk of compound generic semaglutide, which has caused 10 deaths and 100 hospitalizations
- Lai Lai scares, Novo Nordisk saves the scene! The market prospects of weight loss drugs still make many players salivate
-
"영비릉: 2024회계연도 영업수입 동기대비 8% 감소"영비릉은 2024회계연도 재무제보를 발표했다.2024 회계연도 매출은 149억5500만 유로로 전년 동기 대비 8% 감소했습니다.이익은 31억 500만 유로입니다.이익률은 ...- 勇敢的树袋熊1
- 3 일전
- Up
- Down
- Reply
- Favorite
-
계면신문기자 장우발 4분기의 영업수입이 하락한후 텐센트음악은 다시 성장으로 돌아왔다. 11월 12일, 텐센트음악은 최신 재보를 발표했다.2024년 9월 30일까지 이 회사의 3분기 총수입은 70억 2천만 위안으로 전년 ...
- 勇敢的树袋熊1
- 그저께 15:27
- Up
- Down
- Reply
- Favorite
-
본사소식 (기자 원전새): 11월 14일, 다다그룹 (나스닥코드: DADA) 은 2024년 3분기 실적보고를 발표했다. 수치가 보여준데 따르면 고품질발전전략에 지속적으로 전념하고 사용자체험을 끊임없이 최적화하며 공급을 ...- 家养宠物繁殖
- 어제 15:21
- Up
- Down
- Reply
- Favorite
-
11월 12일 소식에 따르면 소식통에 따르면 아마존은 무료스트리밍서비스 Freevee를 페쇄하고 일부 종업원과 프로를 구독서비스 Prime Video로 이전할 계획이다. 올해 초 아마존이 내놓은 몇 편의 대형 드라마의 효 ...- 度素告
- 그저께 13:58
- Up
- Down
- Reply
- Favorite
